Shares Plunge 55% After Patient Death in Erasca Clinical Trial
Erasca, a company specializing in cancer drug development, saw its shares drop by 55% on Tuesday following the withdrawal and subsequent death of a patient in its clinical trial due to severe side effects. This incident has raised widespread concerns about the safety of new drugs.